Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
June 12, 2026
June 12, 2026
NEW YORK, June 12 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:
* * *
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
*
NEW YORK, June 12, 2026 -Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision from the U.S. Food and Drug Administration (FDA) . . .
* * *
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
*
NEW YORK, June 12, 2026 -Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision from the U.S. Food and Drug Administration (FDA) . . .